Brazil Tightens the Screws on Technology Transfer Pricing in Productive Development Partnerships: What the Ministry of Health's New Methodology Means for IP Holders

For more than a decade, Brazil's Productive Development Partnerships (PDPs) have served as one of the country's most strategically important industrial health-policy tools, channeling private-sector technology and manufacturing capability into the public sector to expand access to strategic medicines, vaccines, biologics, and medical devices through the Sistema Único de Saúde (SUS). For multinational pharmaceutical and biotechnology companies, PDPs are also one of the most significant, and procedurally distinctive, vehicles through which know-how, regulatory dossiers, and patent rights are transferred to Brazilian public laboratories.

On April 7, 2026, Brazil's Ministry of Health (MoH), through the Department of the Health Economic-Industrial Complex (DECIS) within the Secretariat of Science, Technology, and Innovation in Health (SCTIE), issued Technical Note No. 14/2026-DECIS/SCTIE/MS (Note), consolidating a structured methodology for valuing technology transfer in PDPs. The Note responds to long-standing determinations of Brazil's Federal Court of Accounts (Tribunal de Contas da União, or TCU), most recently in Panel Decision No. 1.014/2025, and follows the substantive pricing framework first introduced by Informative Note No. 17/2025-DECIS/SCTIE/MS in December 2025.

For practitioners advising clients on Brazilian PDP transactions, this is a meaningful development. The Note formalizes how the value of technology transfer, including know-how, technical and regulatory documentation, dossier rights, and IP transfers or licenses, is to be decomposed, audited, and, where necessary, reimbursed. It also signals a pending complementary regulation, expected by July 2026, that will embed these criteria into the formal regulatory architecture of PDPs under Ordinance GM/MS No. 4.472/2024.

Background: PDPs and the Long Shadow of TCU Oversight

PDPs were designed as hybrid instruments that combine product supply with the gradual internalization of production and regulatory capacity by Brazilian public laboratories (Laboratórios Farmacêuticos Oficiais, or LFOs). A foreign or domestic private partner agrees to supply a strategic health product to the Ministry of Health while progressively transferring the technology, manufacturing know-how, analytical methods, regulatory dossiers, and, in many cases, IP rights or licenses, to a public partner over the life of the partnership. By the conclusion of the PDP, the public laboratory is intended to have full autonomy to manufacture, register, and supply the product.

The TCU, Brazil's federal audit authority, has scrutinized this model for years. In Panel Decision No. 725/2018, later upheld by Panel Decision No. 1.014/2025, the TCU determined that the Ministry of Health should “define the criteria and methodologies to be observed for calculating the value of technology transfer (know-how), including for purposes of establishing contractual penalties.” Notably, the TCU did not prescribe a single pricing formula. Instead, it required minimum guidelines capable of recognizing the diversity of PDP arrangements while ensuring transparency, traceability, and economic-financial balance.

The Core Equation: Splitting Supply from Technology Transfer

At the heart of the Note is a foundational premise reaffirmed by the TCU: in a PDP, supply and technology transfer are inseparable. A PDP is neither a pure procurement contract nor a pure technology-transfer agreement. Removing either element changes the legal and economic nature of the arrangement. With that premise in mind, the Note decomposes the PDP price into two top-level components:

PDP Price = F + BDI

F (Fabricação/Fornecimento) — Manufacturing/Supply: the unit price for production and delivery of the product to the public partner, encompassing raw materials, packaging, direct labor, utilities, quality control, manufacturing overhead, supply logistics, manufacturing-related taxes, and the operational margin on supply.

BDI (Benefícios e Despesas Indiretas) — Indirect Benefits and Expenses: the consolidated rubric for the costs and charges associated with executing the PDP that are not directly attributable to a specific manufacturing input. This is where the Note introduces its most consequential framework.

BDI is decomposed into seven sub-components: CI (Indirect Costs); T (Tax Costs); MC (Contribution Margin for the public producer); Ca (Training and Capacity Building); D (Regulatory Development); L (Technology Licensing - Phase III); and Ce (Valuation of Technology for Definitive Assignment).

The IP-Relevant Components: L and Ce

From an intellectual property perspective, the most consequential elements of the new framework are the L (Licensing) and Ce (Definitive Assignment) components. These are the components in which IP-related assets are most directly concentrated, the temporary use and, ultimately, the irrevocable transfer of the technology package, including technical and regulatory documentation, dossiers, know-how, and IP rights or licenses where applicable.

The Note describes the Phase III Licensing component (L) as a precarious, time- and scope-limited right of use of the regulatory dossier and know-how during the final phase of the PDP. It is typically operationalized through a "clone" registration mechanism, that is, a marketing authorization in the name of the public laboratory, or co-titularity, that permits continuous supply once the private partner has begun its withdrawal but before the technology has been definitively assigned.

The Definitive Assignment component (Ce) is the more substantive of the two. It corresponds to the integral and irrevocable transfer of the technology, with the private partner's complete withdrawal and full autonomy of the public producer. The Note specifies a minimum package that must include authorization to use technical and industrial documentation, definitive assignment of know-how, commitment of non-opposition to future registrations, guarantee of full autonomy, and transfer of intellectual property rights or non-exclusive licenses.

Numerical Benchmarks: New Reference Ranges for Chemically Synthesized Medicines

One of the most concrete contributions of Technical Note No. 14/2026 is the introduction of numerical reference ranges for the BDI components. While Informative Note No. 17/2025 had identified L and Ce as part of the PDP pricing structure, the 2026 Note now goes further by identifying indicative percentage ranges for chemically synthesized medicines.

For these products, the Note identifies Technology Licensing (L) as ranging from 3% to 7% of net sales, and Definitive Assignment (Ce) ranging from 8% to 15% of net sales. The Note expressly contemplates that biologics, vaccines, blood products, and medical devices may warrant different ranges, and that the Ministry has not yet established benchmarks for these higher-complexity categories.

Reimbursement and Indemnification: The Ce Component as the Principal Concern

Perhaps the most important practical contribution of the Note is the framework for reimbursement in the event of early termination or failed technology transfer. The Ce component is the principal locus of reimbursement risk. Because Ce is paid progressively through product purchases but corresponds to a transfer that is only completed at the end of the PDP, proportional reimbursement is appropriate if the partnership terminates early or if the technology transfer is not completed.

The private partner should therefore expect parallel exposure: a proportional refund obligation on the Ce component plus contractual penalty provisions, both potentially triggered by the same termination event. Transparency will be expected throughout the entire lifecycle of the PDP — from price formation and contractual allocation of value to ongoing monitoring and documentation of technology absorption by the public laboratory.

Strategic Implications for Foreign Patent Holders and IP Practitioners

Several aspects of the new framework warrant immediate attention. First, the Ce component's IP package will require careful drafting; private partners wishing to retain commercial rights outside the SUS context should negotiate non-exclusive licenses with carefully delineated field-of-use limitations. Second, the non-opposition commitment should be distinguished clearly between regulatory non-opposition and restraints on enforcement of related patent rights.

Furthermore, the July 2026 complementary regulation will be a watershed moment. When the Ministry issues the binding regulation, the percentage ranges, decomposition requirements, and reimbursement rules will move from methodological guidance to enforceable regulation. For multinational rights holders, Brazil's framework may serve as a reference point in negotiations elsewhere due to its quantitative benchmarks and emphasis on traceability.